These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6803498)

  • 21. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Contraception with pure, synthetic progestogens of the norpregnane group, a new approach for the future?].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1986 Jun; 14(6):577-81. PubMed ID: 12341096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotrophin-release upon iv-administration of a long-acting analogue of luteinizing hormone-releasing hormone in male patients with elevated serum estradiol-concentrations due to chronic liver disease.
    Vierhapper H; Ferenci P; Waldhäusl W
    Endokrinologie; 1980 Dec; 76(3):267-73. PubMed ID: 6781878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
    Bergquist C; Nillius SJ; Wide L
    Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
    Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of follicle-stimulating hormone and luteinizing hormone after subcutaneous administration of human menopausal gonadotropin during pituitary suppression.
    Duijkers IJ; Magnusson YM; Hollanders HM
    Int J Fertil Menopausal Stud; 1995; 40(6):307-10. PubMed ID: 8748920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects.
    Gudmundsson JA; Bergquist C; Nillius SJ
    Prog Clin Biol Res; 1986; 225():337-51. PubMed ID: 2947248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diverse effects of a potent LH-RH antagonist on the LH and FSH release.
    Kovács M; Koppán M; Mezó I; Teplán I
    Acta Biol Hung; 1994; 45(2-4):285-96. PubMed ID: 7725823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
    Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
    Hardt W; Schmidt-Gollwitzer M
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
    Usuki S; Kondoh K; Kubo T
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
    Skarin G; Nillius SJ; Wide L
    Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A; Jean C; Faure N
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral contraception: disadvantages of estrogen reduction].
    Denis C
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty.
    Wilson DA; Hofman PL; Miles HL; Unwin KE; McGrail CE; Cutfield WS
    J Pediatr; 2006 Jan; 148(1):89-94. PubMed ID: 16423605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hormonal changes in buserelin therapy].
    Fuchs U; Zwirner M
    Zentralbl Gynakol; 1989; 111(18):1236-40. PubMed ID: 2511705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
    Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
    Bergquist C; Nillius SJ; Wide L
    Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.